dihexa studies Research Tablet | 25mg Neuroactive Peptide HGF c-Met dihexa clinical trials or human

The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising

Certificate of Analysis Every batch of Bacteriostatic Water supplied by Pepspan comes with a Certificate of Analysis (COA) from the manufacturer

McCoy, A

Were excited